Evaluation of Clinical Decision Support in Opioid Tapering
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT06527079
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Harm Reduction
- Medication Abuse
- Opioid Overdose
- Opioid Prescribing
- Opioid Use Disorder
- Prevention
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 89 Years
- Healthy Volunteers
- Accepted
Interventions
- Opioid Tapering Pathway Clinical Decision Support (CDS) — OTHERClinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
Study Details
The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the risk of withdrawal symptoms, overdose, and to promote tolerance of the tapering. This project will evaluate a clinical decision support (CDS) tool in the form of a clinical care pathway that gives providers information, recommendations, and educational material on strategies for opioid tapering. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will have the clinical care pathway available, but will not be reminded of the pathway when tapering a patient. The intervention arm will receive a nudge when prescribing a tapering opioid strategy to a patient to use the clinical care pathway. The rate of opioid tapering in line with CDC guidelines will be examined as well as long-term patient outcomes of opioid overdose or poisoning using existing patient health records. The study period will be approximately 18 months.
Key Dates
- First listed
- Jul 30, 2024
- Start date
- Aug 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 200,000 participants (estimated)
Arms
- Arm: Usual CareControl group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
- Arm: CDS NotificationProviders will see a clinical decision support tool within the electronic health record when treating a patient who may benefit from or is currently tapering opioid medications to encourage the provider to use a clinical care pathway that provides resources and decision support in tapering.
Primary Outcome Measure
Percentage of encounters tapering within CDC guidelines [ Time Frame: 18 months ]
Central Contacts
- Heather Tolle, PhD303-724-9924
Related Studies
- Houston Emergency Opioid Engagement SystemPHASE4 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Adjunctive Effects of Psilocybin and a Formulation of BuprenorphinePHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use DisorderPHASE2 · Not Yet Recruiting · Wayne State University · Detroit, Michigan
- An Augmented Reality Videogame for Alcohol Use Prevention and Harm Reduction in TeensEnrolling By Invitation · Yale University · New Haven, Connecticut